Logo image of ALSMA.PA

SMAIO SA (ALSMA.PA) Stock Fundamental Analysis

EPA:ALSMA - FR0014005I80 - Common Stock

6.6 EUR
-0.05 (-0.75%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, ALSMA scores 3 out of 10 in our fundamental rating. ALSMA was compared to 57 industry peers in the Health Care Equipment & Supplies industry. While ALSMA seems to be doing ok healthwise, there are quite some concerns on its profitability. ALSMA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSMA has reported negative net income.
ALSMA had a negative operating cash flow in the past year.
ALSMA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALSMA reported negative operating cash flow in multiple years.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.91%, ALSMA is doing worse than 71.93% of the companies in the same industry.
Looking at the Return On Equity, with a value of -34.30%, ALSMA is doing worse than 71.93% of the companies in the same industry.
Industry RankSector Rank
ROA -19.91%
ROE -34.3%
ROIC N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

With an excellent Gross Margin value of 76.70%, ALSMA belongs to the best of the industry, outperforming 85.96% of the companies in the same industry.
In the last couple of years the Gross Margin of ALSMA has declined.
ALSMA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALSMA remains at a similar level compared to 1 year ago.
The number of shares outstanding for ALSMA has been reduced compared to 5 years ago.
Compared to 1 year ago, ALSMA has an improved debt to assets ratio.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALSMA has an Altman-Z score of 4.47. This indicates that ALSMA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.47, ALSMA belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
ALSMA has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALSMA has a Debt to Equity ratio (0.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 4.47
ROIC/WACCN/A
WACC7.62%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

ALSMA has a Current Ratio of 2.71. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
ALSMA has a better Current ratio (2.71) than 77.19% of its industry peers.
ALSMA has a Quick Ratio of 2.27. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
ALSMA's Quick ratio of 2.27 is amongst the best of the industry. ALSMA outperforms 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.27
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALSMA have decreased strongly by -320.37% in the last year.
The Revenue has been growing slightly by 2.12% in the past year.
ALSMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 69.73% yearly.
EPS 1Y (TTM)-320.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.66%
Revenue 1Y (TTM)2.12%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%137.15%

3.2 Future

ALSMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.14% yearly.
The Revenue is expected to grow by 36.55% on average over the next years. This is a very strong growth
EPS Next Y61.25%
EPS Next 2Y55.32%
EPS Next 3Y46.59%
EPS Next 5Y42.14%
Revenue Next Year94.55%
Revenue Next 2Y34.84%
Revenue Next 3Y51.83%
Revenue Next 5Y36.55%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALSMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALSMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSMA's earnings are expected to grow with 46.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.32%
EPS Next 3Y46.59%

More info and screens

0

5. Dividend

5.1 Amount

ALSMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SMAIO SA

EPA:ALSMA (9/4/2025, 7:00:00 PM)

6.6

-0.05 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap37.29M
Analysts86
Price Target7.4 (12.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.57%
PT rev (3m)20.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-40.91%
EPS NY rev (3m)-40.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.78
P/FCF N/A
P/OCF N/A
P/B 5.45
P/tB 8.13
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.97
BVpS1.21
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.91%
ROE -34.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.7%
FCFM N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.44%
Cap/Sales 28.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.27
Altman-Z 4.47
F-Score4
WACC7.62%
ROIC/WACCN/A
Cap/Depr(3y)98.78%
Cap/Depr(5y)137.67%
Cap/Sales(3y)30.2%
Cap/Sales(5y)56.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-320.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.66%
EPS Next Y61.25%
EPS Next 2Y55.32%
EPS Next 3Y46.59%
EPS Next 5Y42.14%
Revenue 1Y (TTM)2.12%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%137.15%
Revenue Next Year94.55%
Revenue Next 2Y34.84%
Revenue Next 3Y51.83%
Revenue Next 5Y36.55%
EBIT growth 1Y-200.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96%
EBIT Next 3YN/A
EBIT Next 5Y43.33%
FCF growth 1Y-153.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-517.2%
OCF growth 3YN/A
OCF growth 5YN/A